Damien Kan
About Damien Kan
Damien Kan is a Software Engineer with extensive experience in the tech industry, having held various roles including Co-Founder and CEO at Shogun and First Software Engineer at Alto Pharmacy. He has worked at several companies in the San Francisco Bay Area and currently serves as Co-Founder and CTO at Meeko Health.
Work at Charlie Health
Damien Kan has been employed at Charlie Health as a Software Engineer since 2022. In this role, he contributes to the development of software solutions aimed at enhancing mental health services. His work focuses on creating efficient and user-friendly applications that support the organization's mission.
Previous Experience at Alto Pharmacy
Damien Kan served as the First Software Engineer at Alto Pharmacy from 2015 to 2019. During his four years in this position, he was instrumental in developing software systems that improved pharmacy operations and patient care. His contributions helped streamline processes within the organization.
Co-Founder and CEO Role at Shogun
In 2015, Damien Kan co-founded Shogun and took on the role of CEO for a duration of ten months. His leadership during this time contributed to the early development of the company, which focuses on e-commerce solutions. His experience in this startup environment provided him with valuable insights into business operations.
Education and Expertise
Damien Kan studied at the University of Southern California from 2006 to 2010, where he focused on Real Estate Development and achieved a degree in Public Policy, Management, and Planning. This educational background has equipped him with a diverse skill set applicable to his roles in software engineering and technology leadership.
Experience at Virta Health
Damien Kan worked as a Software Engineer at Virta Health from 2019 to 2021. In this role, he contributed to the development of software solutions aimed at improving health outcomes for patients. His work involved collaborating with cross-functional teams to enhance the platform's functionality.